Selective Inhibition of AKT Protein Isoforms Augments Gefitinib Response in EGFR Mutated NSCLC Cells

Selective Inhibition of AKT Protein Isoforms Augments Gefitinib Response in EGFR Mutated NSCLC Cells

Bibliographic Details
Main Authors:	Bokobza, S, Devery, A, Weber, A, Jiang, Y, Ryan, A
Format:	Conference item
Published:	2012

Similar Items

Clinical research on the efficacy of self-made sichongsan in combination with gefitinib on NSCLC patients with EGFR mutation
by: Yibo Zhao, et al.
Published: (2018-06-01)

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
by: Makoto Nishio, MD, PhD, et al.
Published: (2022-04-01)

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
by: Bin Zou, et al.
Published: (2018-03-01)

Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer
by: Weber, A, et al.
Published: (2016)

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.
by: Chien-Hung Gow, et al.
Published: (2005-09-01)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
by: Chien-Chung Lin, et al.
Published: (2021-02-01)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
by: Niki Karachaliou, MD, PhD, et al.
Published: (2021-03-01)

Immunohistochemical Detections of EGFR Mutations in NSCLC
by: Chang LIU, et al.
Published: (2014-09-01)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
by: Wang Wen-Ping, et al.
Published: (2012-01-01)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
by: Yuan Ying, et al.
Published: (2012-11-01)

Unexpected responses to EGFR inhibition in NSCLC
by: Giulia M. Stella, et al.
Published: (2015-01-01)

Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy
by: Yuhong Liu, et al.
Published: (2022-07-01)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
by: Jun Li, et al.
Published: (2020-02-01)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
by: Kejun Liu, et al.
Published: (2020-01-01)

FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy
by: Shaoxing Guan, et al.
Published: (2022-09-01)

Efficacy of Gefitinib for Young Patients with Unknown EGFR Gene Mutation  in Advanced Lung Adenocarcinoma
by: Yutao LIU, et al.
Published: (2014-05-01)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
by: Hongbo Zhao, et al.
Published: (2018-11-01)

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
by: Mark S Cragg, et al.
Published: (2007-10-01)

Heterogeneous distribution of EGFR mutation in NSCLC: Case report
by: Sara Boukansa, et al.
Published: (2023-01-01)

Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH.
by: Matthew R Swiatnicki, et al.
Published: (2022-09-01)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
by: Xingyuan Li, et al.
Published: (2023-10-01)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
by: Shu Y, et al.
Published: (2021-11-01)

Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
by: Yanjun Huang, et al.
Published: (2018-07-01)

Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells
by: Haiying LI, et al.
Published: (2016-01-01)

Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients
by: Klaus Hackner, et al.
Published: (2021-02-01)

Gefitinib and EGFR gene copy number aberrations in esophageal cancer
by: Petty, RD, et al.
Published: (2017)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
by: Yingying Jiang, et al.
Published: (2023-05-01)

Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC  (2022 Version)
by: Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee, et al.
Published: (2022-09-01)

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
by: Mikkel G. Terp, et al.
Published: (2021-07-01)

Correlations of <it>EGFR </it>mutations and increases in <it>EGFR </it>and <it>HER2 </it>copy number to gefitinib response in a retrospective analysis of lung cancer patients
by: English John, et al.
Published: (2007-07-01)

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.
by: Silvia La Monica, et al.
Published: (2013-01-01)

The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
by: C.L. Watkins, et al.
Published: (2010-09-01)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
by: Silvia Moreno, et al.
Published: (2021-04-01)

Long term follow-up of EGFR mutated NSCLC cases
by: Gad Rennert, et al.
Published: (2021-01-01)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
by: Jinyao Zhang, et al.
Published: (2021-12-01)

How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?
by: Chuanhao TANG, et al.
Published: (2013-07-01)

TARGETED THERAPY OF NSCLC WITH EGFR ACTIVATING MUTATIONS IMPROVES THE QUALITY OF LIFE OF PATIENTS
by: T. Y. SEMIGLAZOVA, et al.
Published: (2016-12-01)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01)

LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC
by: Xinyin Liu, et al.
Published: (2019-06-01)

Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer
by: Patricia L Theard, et al.
Published: (2020-09-01)